SEC Comment Letter 0000000000-24-006829 to CERENOME, INC. (PSTV)
CERENOME, INC.
Date: June 14, 2024 · CIK: 0001095981 · Accession: 0000000000-24-006829
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280061
Letter
United States securities and exchange commission logo June 14, 2024 Marc H. Hedrick, M.D. Chief Executive Officer Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, TX 78756 Re:Plus Therapeutics, Inc. Registration Statement on Form S-1 Filed June 7, 2024 File No. 333-280061 Dear Marc H. Hedrick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew L. Strong, Esq.
Show Raw Text
United States securities and exchange commission logo
June 14, 2024
Marc H. Hedrick, M.D.
Chief Executive Officer
Plus Therapeutics, Inc.
4200 Marathon Blvd., Suite 200
Austin, TX 78756
Re:Plus Therapeutics, Inc.
Registration Statement on Form S-1
Filed June 7, 2024
File No. 333-280061
Dear Marc H. Hedrick:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrew L. Strong, Esq.